C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) C07K 14/47 (2006.01) C07K 16/18 (2006.01) C12N 5/16 (2006.01)
Patent
CA 2410895
The present invention provides synthetic compounds based on the native human cancer antogen ATF4/CREB-2 antibodies that recognize and bind to these compounds polynucleotides that encode these compounds, and immune effector cells raised in response to the presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
L'invention concerne des composés synthétiques, des anticorps qui reconnaissent et se lient à ces composés, des polynucléotides qui codent pour ces composés, et des cellules effectrices immunes développées en réponse à la présentation de ces épitopes. L'invention concerne aussi des procédés d'induction d'une réponse immune et d'immunothérapie chez un sujet par administration des composés de l'invention.
Borden Ladner Gervais Llp
Genzyme Corporation
LandOfFree
Therapeutic compounds for ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds for ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds for ovarian cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1631164